# OnCo record medulloblastoma-wnt (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/medulloblastoma-wnt/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "medulloblastoma-wnt" ;
  schema:name "WNT-activated medulloblastoma"@en ;
  schema:alternateName "WNT medulloblastoma"@en, "WNT-subgroup medulloblastoma"@en, "CTNNB1-mutant medulloblastoma"@en ;
  schema:description "WNT-activated medulloblastoma is the rarest and most curable of the four molecular groups of medulloblastoma, a brain tumour of the cerebellum. It is driven by a mutation in the beta-catenin gene that switches the WNT growth pathway on. Almost every child is cured with standard therapy, so current trials are asking how much radiotherapy and chemotherapy can be taken away."@en ;
  schema:url <https://onco.cc/cancers/medulloblastoma-wnt/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Medulloblastoma> ;
  schema:citation <https://en.wikipedia.org/wiki/Medulloblastoma>, <https://www.cancer.gov/types/brain/hp/child-cns-embryonal-treatment-pdq> ;
  onco:tag "subtype-page", "paediatric", "cns" ;
  onco:related <https://onco.cc/cancers/medulloblastoma-shh/>, <https://onco.cc/cancers/medulloblastoma-group-3-4/> ;
  onco:technologies <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/methylation-profiling/> ;
  onco:institutions <https://onco.cc/institutions/st-jude/>, <https://onco.cc/institutions/childrens-oncology-group/>, <https://onco.cc/institutions/siop-europe/> ;
  onco:pathways <https://onco.cc/pathways/wnt/> ;
  onco:terms <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/medulloblastoma-molecular-groups/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-who-2021-cns-louis-neuro-oncology-2021/>, <https://onco.cc/key-papers/paper-taylor-medulloblastoma-consensus-acta-neuropathol-2012/>, <https://onco.cc/key-papers/paper-cavalli-medulloblastoma-subtypes-cancer-cell-2017/>, <https://onco.cc/key-papers/paper-acns0331-michalski-jco-2021/> ;
  onco:pipeline <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/germline-testing/> ;
  onco:standardOfCare <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/lomustine/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/institutions/st-jude/>, <https://onco.cc/institutions/childrens-oncology-group/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/technologies/survivorship-care-plan/> .